The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer

Chinese Journal of Cancer

Volumn 33, Issue 2, 2014, Pages 105-114

  Zhang, Jian Wei ^a   Zhao, Yuan Yuan ^a   Guo, Ying ^a,b   Xue, Cong ^a   Hu, Zhi Huang ^a   Huang, Yan ^a   Zhao, Hong Yun ^a   Zhang, Jing ^a   Wu, Xuan ^a   Fang, Wen Feng ^a   Ma, Yu Xiang ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Sun Yatsen Medical University   (China)

Author keywords

Correlation; EGFR TKIs; NSCLC; Overall survival; Platinum based doublet chemotherapy

Indexed keywords

BEVACIZUMAB; BEXAROTENE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; VADIMEZAN;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84893468510     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10274     Document Type: Article

References (42)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin, 1999,49:8-31.
2. Novello S, Le Chevalier T. Chemotherapy for non-small cell lung cancer. Part 1: early-stage disease. Oncology (Williston Park), 2003,17:357-364.
3. Group NM-AC. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol, 2008,26:4617-4625.
4. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin, 2010,60:277-300.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002,346:92-98.
6. Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc, 2009,6:233-241.
7. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as firstline chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 2009,27:3217-3224.
8. Scagliotti GV, Parikh P, Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced stage non-small cell lung cancer. J Clin Oncol, 2008,26:3543-3551.
9. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol, 2008,26:5589-5595.
10. Grothey A, Sargent D, Goldberg R, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 2004,22:1209-1214.
11. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or singleagent therapy is used first line. J Clin Oncol, 2005,23:9441-9442.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med, 2005,353:123-132.
13. Laack E, Schneider C, Gutjahr T, et al. Association between different potential predictive markers from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC). J Clin Oncol, 2007, 18 Suppl:abstr 7651.
14. Garassino MC, Martelli O, Bettini A, et al. A phase III trial comparing erlotinib versus docetaxel as second-line treatment of NSCLC patients with wild-type EGFR. J Clin Oncol, 2012,30 Suppl:abstr LBA7501.
15. Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutation in non-small cell lung cancer. Clin Cancer Res, 2006,12:7232-7241.
16. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer: search and destroy. Eur J Cancer, 2006,42:17-23.
17. Soo RA, Loh M, Mok TS, et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. J Thorac Oncol, 2011,6:1030-1038.
18. Zhou W, Christiani DC. East meets west: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer, 2011,30:287-292.
19. Zhou CC, Wu YL, Chen GY, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011,12:735-742.
20. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010,11:121-128.
21. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012,13:239-246.
22. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med, 2010,362:2380-2388.
23. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009,361:947-957.
24. Han JY, Park L, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol, 2012,30:1122-1128.
25. National Comprehensive Cancer Network-Asia. Non-small cell lung cancer: treatment guidelines for patients. Version 1.
26. Xue C, Hu ZH, Jiang W, et al. National survey of the medical treatment status for non-small-cell lung cancer in China. Lung Cancer, 2012,77:371-375.
27. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol, 2005,23:5892-5899.
28. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-intact 1. J Clin Oncol, 2004,22:777-784.
29. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial-intact 2. J Clin Oncol, 2004,22:785-794.
30. Baselga J. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small cell lung cancer: how do we go from INTACT to impact? J Clin Oncol, 2004,22:759-761.
31. Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol, 2010,28:5240-5246.
32. Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol, 2008,9:1135-1142.
33. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol, 2007,18:317-323.
34. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol, 2004,22:254-261.
35. Lara PN Jr, Douillard JY, Nakagawa K, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer. J Clin Oncol, 2011,29:2965-2971.
36. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabinewith either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol, 2009,27:1227-1234.
37. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol, 2010,28:911-917.
38. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 2009,373:1525-1531.
39. Tan EH, Rolski J, Grodzki T, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and I.V. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced nonsmall cell lung cancer. Ann Oncol, 2009,20:1249-1256.
40. Ramlau R, Zatloukal P, Jassem J, et al. Randomized phase III trial comparing bexarotene (l1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer: SPIRIT I. J Clin Oncol, 2008,26: 1886-1892.
41. Blumenschein GR Jr, Khuri FR, von Pawel J, et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer: SPIRIT II. J Clin Oncol, 2008,26:1879-1885.
42. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355:2542-2550.